NCQA Unveils 2026 Health Plan Ratings

NCQA's 2026 Health Plan Ratings awarded 18 plans a 5-star rating, a 64% increase from 2025, while another 53 plans received 4.5 stars. Average quality benchmarks rose 1.6-1.8 percentage points across commercial, Medicaid and Medicare Advantage plans, with Medicaid improving on 89% of measures. Behavioral-health follow-up after hospitalization improved by 8.9 points in commercial plans, 9.0 points in Medicaid and 11.9 points in Medicare Advantage, signaling broad gains in care quality and coordination.

Analysis

This is a weak standalone trading signal: the ratings are voluntary, backward-looking, and increasingly compressed across plans, limiting their usefulness as a near-term indicator of enrollment or earnings. The more relevant implication is that quality performance is becoming table stakes rather than a differentiator; plans that cannot match peer improvement may face higher retention costs, broker pressure, and potentially weaker positioning in state Medicaid procurements over the next 6-18 months.

The broad improvement in behavioral-health follow-up and chronic-care measures likely reflects sustained spending on care-management workflows, provider outreach, and data integration. That favors scaled managed-care organizations with internal clinical infrastructure—UNH, ELV, HUM, CNC and MOH—but also raises the risk that operating-cost growth persists after quality gains have already been recognized. For MA, the key financial question is whether quality execution offsets the continuing CMS rate and risk-adjustment headwinds; NCQA scores do not directly translate into CMS Star bonus payments.

Second-order beneficiaries are healthcare IT and services vendors tied to HEDIS abstraction, member engagement, and care-gap closure, including VEEV, Doximity (DOCS), and private-equity-heavy care-management vendors, although no public-company revenue read-through can be established from this release. The contrarian point is that narrowing quality dispersion reduces the value of broad "best-in-class quality" narratives: procurement and consumers may increasingly decide on network breadth, premium, and benefit design, intensifying price competition—especially in Medicaid managed care.

Near term, await plan-level rating detail and state procurement calendars rather than positioning on the aggregate release. A material divergence between NCQA quality gains and 2027 medical-cost or administrative-expense guidance would signal that quality investment is becoming margin-dilutive rather than commercially productive.

Key Decisions for Investors

• No immediate directional trade on the aggregate announcement; treat it as an alert to review plan-level results for UNH, ELV, HUM, CNC and MOH once published, with emphasis on whether weaker-rated subsidiaries overlap with upcoming Medicaid rebids.
• Maintain a 6-12 month relative preference for ELV and UNH over Medicaid-heavy CNC/MOH if procurement evidence shows quality metrics gaining weight: larger diversified platforms can amortize care-management technology and compliance expense across commercial, MA and Medicaid books.
• Do not use NCQA ratings as a proxy for MA Star revenue. For HUM and UNH, require confirmation through CMS Star previews, 2027 rate notices, and MA membership guidance; a CMS adverse adjustment would outweigh any reputational benefit from quality improvement.
• Watch managed-care administrative-cost guidance in the next two earnings cycles. If SG&A rises while medical-cost trend remains elevated, consider a defensive pair—short CNC versus long ELV—only after evidence that Medicaid quality investments are not translating into contract economics; invalidate if CNC demonstrates rebid wins or margin recovery ahead of guidance.